Catalyst Wire Dossier Catalyst Wire Dossier

Pneumococcal polysaccharide vaccine (23-valent)

pneumococcal polysaccharide vaccine (23-valent) · Walvax Biotechnology Co., Ltd.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Pneumococcal polysaccharide vaccine (23-valent), covering 2014-11-06 to 2019-01-31. Get the full timeline:

Most recent: Clinical Trial Update: The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine [Phase 4]

See pricing